Cancer

A new immunotherapy approach shows that engineered T cells are able to penetrate into pancreatic tumors and directly attack the cancer

The epithelial-to-mesenchymal transition in pancreatic cancer may play a role in its resistance to treatment – and inhibiting it may improve treatment efficacy

Pancreatic cancer is tough to understand, diagnose and treat. Undeterred researchers are on a quest to crack the case.

The vast majority of experimental cancer drugs fail during the later stages of clinical development

Revolutionary cancer immunotherapies appear to alleviate Alzheimer’s symptoms in mice

Intercepting communication between cancer cells and endothelium uncovers clues to metastasis mechanisms

Could exosome encapsulation be the secret to delivering higher potency in chemotherapy?

Now I have a lab of my own, I’ve found that the best research comes from finding the right collaborators.

Robert Coffin tells the bench-to-bedside story of how the first FDA-approved oncolytic virotherapy, talimogene laherparepvec (T-VEC), was translated from a colleague’s cold sore to a potential global game changer.

The combination of genomic profiling and high-tech targeted drug delivery is opening up a new front in the fight against cancer.